Challenging Cases in Neuro-Oncology

Abstract

Neuro-oncology encompasses a broad field focusing on an array of neoplasms, many of which can mimic several diseases. Neurologists will often be involved in the initial diagnostic evaluation and management of these patients. Their insight is central to optimizing the diagnostic yield and providing high-level clinical care. Several neuro-oncologic cases are reviewed with a goal of increasing the understanding of these diseases in a clinically relevant manner and providing updates on the contemporary thinking in the subspecialty.

Keywords

CNS lymphoma - glioma - H3K27M - pleomorphic xanthoastrocytoma - Rosai-Dorfman disease

Publikationsverlauf

Accepted Manuscript online:
23. November 2022

Artikel online veröffentlicht:
22. Dezember 2022

• References

• 1 Lukas RV, Stupp R, Gondi V, Raizer JJ. Primary central nervous system lymphoma - Part 1: Epidemiology, diagnosis, staging, and prognosis. Oncology (Williston Park) 2018; 32 (01) 17-22
• 2 Zhou XW, Wang X, Yang Y. et al. Biomarkers related with seizure risk in glioma patients: a systematic review. Clin Neurol Neurosurg 2016; 151: 113-119
• 3 Chen H, Judkins J, Thomas C. et al. Mutant IDH1 and seizures in patients with glioma. Neurology 2017; 88 (19) 1805-1813
• 4 Easwaran TP, Lancki N, Henriquez M. et al. Molecular classification of gliomas is associated with seizure control: a retrospective analysis. Neuromolecular Med 2021; 23 (02) 315-326
• 5 Barajas Jr RF, Politi LS, Anzalone N. et al. Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro-oncol 2021; 23 (07) 1056-1071
• 6 Lukas RV, Riedell P, Horowitz PM, Pytel P, Kamson DO. Diagnostic evaluation in primary CNS lymphoma. Neurologist 2018; 23 (02) 53-54
• 7 Kam KL, Brooker SM, Mao Q. et al. Newly diagnosed enhancing lesions: steroid initiation may impede diagnosis of lymphoma involving the central nervous system. J Clin Neurosci 2020; 81: 61-64
• 8 Ferreri AJM, Holdhoff M, Nayak L, Rubenstein JL. Evolving treatments for primary central nervous system lymphoma. Am Soc Clin Oncol Educ Book 2019; 39: 454-466
• 9 Lukas RV, Gondi V, Stupp R, Raizer JJ. Primary central nervous system lymphoma-Part 2: modern therapeutic management and future directions. Oncology (Williston Park) 2018; 32 (02) e11-e19
• 10 Rae AI, Mehta A, Cloney M. et al. Craniotomy and survival for primary central nervous system lymphoma. Neurosurgery 2019; 84 (04) 935-944
• 11 Karmali R, Nabhan C, Petrich AM. et al. Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma. Br J Haematol 2017; 177 (01) 72-79
• 12 Nakajima K, Mizobuchi Y, Fujihara T, Azumi M, Takagi Y. Continued maintenance therapy with high-dose methotrexate improves overall survival of patients with primary central nervous system lymphoma. J Med Invest 2021; 68 (3.4): 286-291
• 13 Tsang M, Rubenstein JL, Pulczynski EJ. Primary central nervous system lymphoma in older adults and the rationale for maintenance strategies: a narrative review. Ann Lymphoma 2021; 5: 25
• 14 Du S, Bota D, Kong XT. Successful consolidation/maintenance therapy with single agent ibrutinib for primary CNS lymphoma after initial induction therapy. Neurol Int 2022; 14 (03) 574-580
• 15 Buerki RA, Horbinski CM, Kruser T, Horowitz PM, James CD, Lukas RV. An overview of meningiomas. Future Oncol 2018; 14 (21) 2161-2177
• 16 Lee EQ. Nervous system metastases from systemic cancer. Continuum (Minneap Minn) 2015; 21 (2 Neuro-Oncology) 415-428
• 17 Ostrom QT, Cioffi G, Gittleman H. et al. CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro-oncol 2019; 21 (Suppl 5): v1-v100
• 18 Louis DN, Perry A, Reifenberger G. et al. The 2016 World Health Organization Classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016; 131 (06) 803-820
• 19 Doglioni C. Rosai-Dorfman disease. A legacy of Professor Rosai that is still not exploited completely. Pathologica 2021; 113 (05) 388-395
• 20 Rech KL, He R. Challenges in the histopathologic diagnosis of histiocytic neoplasms. J Natl Compr Canc Netw 2021; 19 (11) 1305-1311
• 21 Salama HA, Jazieh AR, Alhejazi AY. et al. Highlights of the management of adult histiocytic disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, Rosai-Dorfman disease, and hemophagocytic lymphohistiocytosis. Clin Lymphoma Myeloma Leuk 2021; 21 (01) e66-e75
• 22 Shaikh N, Brahmbhatt N, Kruser TJ. et al. Pleomorphic xanthoastrocytoma: a brief review. CNS Oncol 2019; 8 (03) CNS39
• 23 Kaley T, Touat M, Subbiah V. et al. BRAF inhibition in BRAFV600-mutant gliomas: results from the VE-BASKET study. J Clin Oncol 2018; 36 (35) 3477-3484
• 24 Wen PY, Stein A, van den Bent M. et al. Dabrafenib plus trametinib in patients with BRAF^V600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol 2022; 23 (01) 53-64
• 25 Rudà R, Capper D, Waldman AD. et al. EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors. Neuro-oncol 2022; 24 (12) 2015-2034
• 26 Mosaab A, El-Ayadi M, Khorshed EN. et al. Histone H3K27M overrides histological grading in pediatric gliomas. Sci Rep 2020; 10 (01) 8368
• 27 Schulte JD, Buerki RA, Lapointe S. et al. Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. Neurooncol Adv 2020; 2 (01) vdaa142
• 28 Singer LS, Feldman AZ, Buerki RA, Horbinski CM, Lukas RV, Stupp R. The impact of the molecular classification of glioblastoma on the interpretation of therapeutic clinical trial results. Chin Clin Oncol 2021; 10 (04) 38
• 29 Argersinger DP, Rivas SR, Shah AH, Jackson S, Heiss JD. New developments in the pathogenesis, therapeutic targeting, and treatment of H3K27M-mutant diffuse midline glioma. Cancers (Basel) 2021; 13 (21) 5280
• 30 Chi AS, Tarapore RS, Hall MD. et al. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J Neurooncol 2019; 145 (01) 97-105
• 31 Cantor E, Wierzbicki K, Tarapore RS. et al. Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma. Neuro-oncol 2022; 24 (08) 1366-1374
• 32 Horbinski C, Ligon KL, Brastianos P. et al. The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-oncol 2019; 21 (12) 1498-1508
• 33 Kam KL, Appin CL, Mao Q. et al. Is next-generation sequencing alone sufficient to reliably diagnose gliomas?. J Neuropathol Exp Neurol 2020; 79 (07) 763-766